October 25, 2023

TO: Members of the Board of Trustees

FROM: Anne D’Alleva, Ph.D.  
Provost and Executive Vice President for Academic Affairs

RE: Reappointment of Board of Trustees Distinguished Professor Diane J. Burgess to the Pfizer Distinguished Chair in Pharmaceutical Technology in the School of Pharmacy

RECOMMENDATION:

That the Board of Trustees approve the reappointment of Board of Trustees Distinguished Professor of Pharmaceutics Diane J. Burgess to the Pfizer Distinguished Chair in Pharmaceutical Technology in the School of Pharmacy.

BACKGROUND:

The School of Pharmacy unanimously supports the Board of Trustees Distinguished Professor of Pharmaceutics Diane J. Burgess’ reappointment as the Pfizer Distinguished Chair in Pharmaceutical Technology. The Board established the Pfizer Distinguished Chair in Pharmaceutical Technology on August 3, 2004. Professor Burgess’ five-year reappointment will run through August 22, 2028.

Dr. Burgess joined the University of Connecticut in 1993 as an Associate Professor and was promoted to Professor in 1999. In 2009, Professor Burgess was appointed Board of Trustees Distinguished Professor of Pharmaceutics.

Dr. Burgess has demonstrated an outstanding record during her term as the Pfizer Distinguished Chair in Pharmaceutical Technology. She has pushed the boundaries of pharmaceutical technology research and maintains a national and international reputation.

Dr. Burgess’s has mentored numerous graduate students, postdoctoral fellows, research assistant professors, and visiting research fellows. She has supported the Pharmaceutics discipline's membership in the Center for Pharmaceutical Processing Research (CPPR), and her contributions to the National Institute for Pharmaceutical Technology and Innovation (NIPTE) have significantly enriched the research landscape in pharmaceutical processing.

Dr. Burgess has secured over $6 million in new funding from federal agencies and private entities. Equally remarkable is the success of DIANT Pharma, a startup co-founded by Professor Burgess and Dr. Antonio Costa, a former member of her research team. DIANT Pharma’s achievement in continuous manufacturing equipment sales to pharmaceutical companies has already surpassed $3 million, further contributing to economic growth and employment opportunities within our state.